Last reviewed · How we verify

FF/UMEC/VI (100/31.25/25) mcg

GlaxoSmithKline · Phase 3 active Small molecule

FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease.

FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameFF/UMEC/VI (100/31.25/25) mcg
SponsorGlaxoSmithKline
Drug classTriple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist
TargetGlucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

Fluticasone furoate (FF) is an inhaled corticosteroid that reduces airway inflammation. Umeclidinium (UMEC) is a long-acting muscarinic antagonist that provides bronchodilation by blocking acetylcholine receptors. Vilanterol (VI) is a long-acting beta-2 agonist that further enhances bronchodilation. Together, these three agents work synergistically to improve lung function and reduce exacerbations in COPD patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: